News for PFIZER INC (PFECL.SN)

Summary Pfizer Inc (PFE) announced on April 26, 2025, the results from its Phase 3 CREST trial, which evaluated the efficacy of sasanlimab, an investigational a

Pfizer's (PFE) Phase 3 CREST trial of sasanlimab with BCG shows 32% reduction in disease-related events. Trial met primary endpoint, sig

Reviewing PFE’s five-year history, the stock has experienced a balanced 50-50 distribution of positive and negative returns after earnings releases.

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that (1) sold or otherwise

Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour BR

Summary Pfizer Inc (PFE) has announced that its board of directors has declared a $0.43 dividend for the second quarter of 2025. This dividend will be payable o

Summary Pfizer Inc (PFE) announced its participation in the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled from May 30 to June 3 in

Pfizer (PFE) declares a second-quarter 2025 cash dividend of $0.43 per share. The dividend is set for payment on June 13, 2025, to shareholders recorded

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company's common stock, payable June 1

Quick Summary: Pfizer (PFE) maintains a stable dividend with a forward yield of 7.68%. Analysts project a potential 30.09% upside based on average price

Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (A

The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations.

We recently published a list of Jim Cramer’s Thoughts on These 5 Stocks. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discussed. On Thursday’s episode of Mad Money, Jim Cramer addressed the growing friction between Federal Reserve Chairman Jerome Powell and […]

We recently published a list of 15 Recent Activist Investor Campaigns. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other recent activist investor campaigns. Economic uncertainty and market volatility are some of the factors fueling activist investor campaigns in 2025. In the first quarter alone, there […]

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

We recently published a list of the 10 Safe Dividend Stocks with Yields Above 5%. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other safe dividend stocks. Dividend-paying stocks have long held a special place among investors, often delivering stronger returns than the broader market over time. […]

Bank of America has revised its price target for Pfizer (PFE), lowering it from $29 to $26, while maintaining a Neutral rating for the pharmaceutical giant's sh

Summary: Pfizer's stock has dropped by 24.46% due to acquisitions and cost structure changes. Activist investor Starboard Value has taken a $1 billion st

We recently published a list of Jeff Smith’s Top 10 Activist Targets and Their Returns Compared to the S&P 500. In this article, we are going to take a look at where Pfizer Inc.